MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Lista de Ações・Editas Medicine Inc

Editas Medicine Inc

Fechado

SetorSaúde

2.04 -0.49

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.02

Máximo

2.04

Indicadores-chave
By Trading Economics
Rendimento	28M -25M
Vendas	4M 7.5M
Margem de lucro	-332.984
Funcionários	246
EBITDA	27M -22M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+96.1% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-70M 205M
Abertura anterior	2.53
Fecho anterior	2.04

Sentimento de Notícias

By Acuity

68%

32%

330 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

1.33 / 1.54 Suporte e Resistência

Editas Medicine Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jan. de 2026, 22:45 UTC

Grandes Movimentos do Mercado

GH Research Shares Up, Plans to Provide Update on New Drug Application

4 de jan. de 2026, 23:50 UTC

Conversa de Mercado

Notícias Principais

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4 de jan. de 2026, 23:50 UTC

Conversa de Mercado

Notícias Principais

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4 de jan. de 2026, 23:41 UTC

Conversa de Mercado

Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

4 de jan. de 2026, 23:40 UTC

Conversa de Mercado

Notícias Principais

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4 de jan. de 2026, 23:35 UTC

Conversa de Mercado

Notícias Principais

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4 de jan. de 2026, 23:19 UTC

Conversa de Mercado

Notícias Principais

Global Energy Roundup: Market Talk

4 de jan. de 2026, 23:19 UTC

Conversa de Mercado

Notícias Principais

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4 de jan. de 2026, 23:17 UTC

Notícias Principais

Spot Gold Rises 0.8% to $4,365.24/oz

4 de jan. de 2026, 23:16 UTC

Notícias Principais

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4 de jan. de 2026, 23:14 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4 de jan. de 2026, 23:13 UTC

Notícias Principais

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4 de jan. de 2026, 23:12 UTC

Conversa de Mercado

Notícias Principais

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4 de jan. de 2026, 22:37 UTC

Conversa de Mercado

Notícias Principais

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4 de jan. de 2026, 21:00 UTC

Ganhos

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4 de jan. de 2026, 20:49 UTC

Conversa de Mercado

Notícias Principais

Global Energy Roundup: Market Talk

4 de jan. de 2026, 20:49 UTC

Conversa de Mercado

Notícias Principais

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3 de jan. de 2026, 18:59 UTC

Notícias Principais

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 de jan. de 2026, 17:42 UTC

Notícias Principais

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3 de jan. de 2026, 17:40 UTC

Notícias Principais

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 de jan. de 2026, 16:10 UTC

Notícias Principais

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3 de jan. de 2026, 15:53 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 15:03 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 14:10 UTC

Notícias Principais

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 de jan. de 2026, 12:16 UTC

Notícias Principais

U.S. Captures Maduro, Trump Says -- Barrons.com

3 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

3 de jan. de 2026, 09:20 UTC

Conversa de Mercado

Ganhos

Auto & Transport Roundup: Market Talk

3 de jan. de 2026, 00:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Research Reports -- Barrons.com

2 de jan. de 2026, 22:13 UTC

Conversa de Mercado

Ganhos

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

Comparação entre Pares

Variação de preço

Editas Medicine Inc Previsão

Preço-alvo

By TipRanks

96.1% parte superior

Previsão para 12 meses

Média 4.02 USD 96.1%

Máximo 5 USD

Mínimo 3 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Editas Medicine Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Editas Medicine Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.33 / 1.54Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentimento

By Acuity

330 / 374 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.